ACQUISITIONS (Details) (USD $)	3 Months Ended								12 Months Ended											12 Months Ended					12 Months Ended
	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 29, 2012	Jun. 30, 2012	Mar. 29, 2014	Mar. 30, 2013	Mar. 31, 2012	Mar. 29, 2014 Hemerus Medical, LLC [Member]	Apr. 30, 2013 Hemerus Medical, LLC [Member]	Mar. 29, 2014 Hemerus Medical, LLC [Member] Acquired technology	Mar. 29, 2014 Hemerus Medical, LLC [Member] Trade names	Mar. 29, 2014 Hemerus Medical, LLC [Member] Customer relationship	Mar. 29, 2014 Hemerus Medical, LLC [Member] FDA Approval of SOLX [Member]	Mar. 30, 2013 Hemerus Medical, LLC [Member] FDA Approval of SOLX [Member]	Mar. 29, 2014 Hemerus Medical, LLC [Member] Future Sales of SOLX [Member]	Mar. 29, 2014 Pall Corporation [Member]	Mar. 30, 2013 Pall Corporation [Member]	Aug. 01, 2012 Pall Corporation [Member]	Mar. 30, 2013 Pall Corporation [Member] Acquired technology	Mar. 30, 2013 Pall Corporation [Member] Customer relationship	Mar. 29, 2014 Pall Corporation [Member] Acquired Technology and Customer Relationships	Mar. 30, 2013 Pall Corporation [Member] Acquired Technology and Customer Relationships	Aug. 01, 2012 Pall Corporation [Member] Replication and Delivery of Certain Manufacturing Assets [Member]
Business Acquisition [Line Items]
Consideration paid													$ 24,100,000									$ 535,200,000
Contingent consideration, maximum																	3,000,000		14,000,000								15,000,000
Allocation of purchase price
Inventories																					49,917,000
Property, plant and equipment																					85,984,000
Intangible assets														22,800,000	1,900,000	600,000					188,500,000		61,000,000	127,500,000
Other assets/liabilities, net																					(6,166,000)
Goodwill	336,768,000				330,474,000				336,768,000	330,474,000	115,058,000	6,425,000									216,940,000
Fair value of net assets acquired												31,725,000									535,175,000
Amortization expense									29,200,000	22,100,000	11,400,000	2,300,000													15,700,000	10,500,000
Consideration transfered in shares																						500,000
Contingent consideration amount owed																	7,645,000	7,600,000
Long-term debt	440,287,000								440,287,000
Useful life																									12 years	12 years
Net revenues	241,091,000	242,120,000	235,755,000	219,543,000	249,942,000	247,395,000	218,178,000	176,475,000	938,509,000	891,990,000	727,844,000									190,698,000	138,400,000
Net Sales																					963,923,000
Net Income																					$ 56,540,000
Basic EPS																					$ 1,100
Diluted EPS																					$ 1,080